drugset / Trial / NCT00666692
A Phase 1b Study With Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in First-line, Advanced Non-small Cell Lung Cancer (NSCLC)
NaSingle-groupOpen-labelTreatment
Summary
The primary purpose of this study is to examine the safety of volociximab (V) in combination with a standard treatment of carboplatin (C), paclitaxel (P), and bevacizumab (B) in subjects previously untreated with chemotherapy for advanced stage (IIIB/IV) non-squamous non-small cell lung cancer (NSCLC).
Timeline
- Start
- 2008-04
- Primary completion
- 2008-10
- Completion
- 2008-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Volociximab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Volociximab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Volociximab | Monoclonal antibody | 20 mg/kg | Intravenous |
| Subject | Volociximab | Monoclonal antibody | 30 mg/kg | Intravenous |
| Background | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Background | Carboplatin | Small molecule | 6 unknown | Intravenous |
| Background | Paclitaxel | Small molecule | 200 mg/m2 | Intravenous |